R. W. Dal Negro (Verona, Italy), B.J. O'Connor (London, United Kingdom)
Siccine acid effects in patients with exacerbation of severe COPD
M. Sanzharovskaya, G. Chernogoryuk, V. Khazanov (Tomsk, Russian Federation)
|   |
Time dependent changes in the individual domains of the SGRQ. Results of the TORCH trial
P. Jones, P. Calverley, B. Celli, J. Anderson, G. Ferguson, C. Jenkins, J. Yates, J. Vestbo (London, Liverpool, Greenford, Manchester, United Kingdom; Boston, MA, Livonia, MI, RTP, NC, United States Of America; Sydney, Australia)
| |
Reliability of death certificates regarding COPD mortality in the TORCH study
L. McGarvey, M. Zvarich, J. Anderson, N. Thomas, M. John, R. Wise (Belfast, Greenford, United Kingdom; RTP, NC, Baltimore, MD, United States Of America; Prerow, Germany)
| |
Seasonal pattern of exacerbation rates in the tiotropium clinical trial database
D. Dusser, D. Niewoehner, A. Anzueto, I. Leimer, A. Furtwaengler (Paris, France; Minneapolis, San Antonio, United States Of America; Ridgefield, Ingelheim, Germany)
| |
Psychometric evaluation of the living with chronic obstructive pulmonary disease (LCOPD) questionnaire
S. McKenna, D. Meads, D. Revicki, R. Flood, A. Glendenning (Manchester, Horsham, United Kingdom; Bethesda, United States Of America)
| |
Pathogenic therapy of patients with chronic obstructive pulmonary diseases (COPD)
T. Pertseva, O. Myronenko, O. Plekhanova (Dnipropetrovs‘k, Ukraine)
| |
The effect of tiotropium in COPD complicated with asthma
T. Iwanaga, E. Naito, H. Ichihashi, S. Kitaguchi, Y. Ikeda, A. Sano, R. Sato, F. Tsuji, T. Miyara, H. Sano, M. Muraki, H. Kubo, Y. Tohda (Osakasayama, Osaka, Japan)
| |
Comorbid conditions reported in patients with COPD recruited into clinical trials
M. Decramer, D. Tashkin, D. Mannino, I. Leimer, S. Kesten (Leuven, Belgium; Los Angeles, Lexington, United States Of America; Ingelheim, Germany)
| |
Effect of inhaled budesonide on BAL inflammatory cells and MMP-12 expression in COPD
A. Babusyte, K. Stravinskaite, J. Jeroch, R. Sakalauskas, B. Sitkauskiene (Kaunas, Lithuania)
| |
Can the use of adaptive aerosol delivery technology increase the quality of life for patients with COPD?
N. Goodman, S. Hinch, S. Coughlin, M. Morgan, K. Nikander (Chichester, Leicester, United Kingdom)
| |
Use of 6-min (6M) and 12 min (12M) walking test (WT) for assessing the efficacy of formoterol (F)
G. L. Biscione, F. Pasqua, G. Crigna, L. Martone, V. Cardaci, L. Ferri, M. Cazzola (Velletri, Rome, Italy)
| |
Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD
A. K. Bhattacharya, S. Bhargav, V. Singh, D. Talwar, J. Whig, S. Naik, C. J. Po, S. M. Purandare, A. Sule, J. A. Gogtay (Ahmedabad, Indore, Jaipur, Noida, Ludhiana, Mumbai, India)
| |
Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial
A. Sergey, N. Galiya, B. Sanjita, S. Olga, C. Alexander (Moscow, Russian Federation)
| |
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data
V. Brusasco, R. Hodder, D. Briggs, I. Leimer, S. Kesten (Genoa, Italy; Ottawa, Canada; Birmingham, United States Of America; Ridgefield, Ingelheim, Germany)
| |
Preventive effect on acute exacerbation of COPD with carbocisteine (PEACE study in China)
J. Zheng, J. Kang, P. Chen, S. Huang, W. Yao, N. Zhong (Guangzhou, Guangdong, Shenyang, Liaoning, Shanghai, Beijing, China)
| |
Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers
S. Khalilieh, M. Tsai, S. van Marle, M. Kraan (Kenilworth, NJ, United States Of America; Zuidlaren, Netherlands)
| |
A 6 week study of the efficacy and safety of UK-500,001 dry powder for inhalation (DPI) in adults with chronic obstructive pulmonary disease (COPD)
J. Vestbo, L. Tan, G. Atkinson (Manchester, Sandwich, United Kingdom)
| |
Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers
S. Khalilieh, M. Tsai, D. de Vries, M. Kraan (Kenilworth, NJ, United States Of America; Leiden, Netherlands)
| |
Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults
S. Khalilieh, C. Kasserra, M. Tsai, M. Seiberling, M. Kraan (Kenilworth, NJ, United States Of America; Allschwil, Switzerland)
| |
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD
K. Beeh, J. Beier, U. Liebers, A. Schumacher, M. Meyer, D. Bock, G. Wolff, C. Witt (Wiesbaden, Berlin, Hennigsdorf, Germany)
| |